@article {Anandarajah3650作者={亚伦Anandarajah和Alexa沃特和詹姆斯贵港市希(merrill Lynch)和安德里亚·施奈德和丹尼尔Sandsmark雷蒙Diaz-Arrastia}, title ={时间到达医院和临床之间的关系和流体生物标志物的结果在创伤性脑损伤(好- 7.003)},体积={100}={17补充2},elocation-id = {3650} = {2023}, doi = {10.1212 / WNL。出版商0000000000203423}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:确定相关变量延迟急诊科(ED)创伤性脑损伤(TBI)后表示。首页背景:创伤性脑损伤后延迟表示ED可能有所不同根据人口和临床变量和可能混淆的解释临床评估和血液生物标志物检测。设计/方法:非穿透患者创伤性脑损伤后被录取进入城市创伤中心。在损伤和ED的到来归类为\ < 1小时,1 {\ textendash} 6小时,和\ > 6小时。血液是1天,3天,2周,具有抑制受损和分析延伸和6个月使用Simoa HD-X Neuro4plex化验NfL, GFAP和UCH-L1水平。人口统计变量和临床结果的到达时间范畴与卡方或克鲁斯卡尔-沃利斯测试评估。为流体blood-biomarkers log2到达时间之间的水平比较类别使用单向方差分析。结果:187创伤性脑损伤的患者(平均年龄47.7岁,71 \ %男,50 \ %的白色,和中间的格拉斯哥昏迷评分(GCS) 15)都包括在这个分析中。60 \ %抵达\ < 1小时,24 \ % 1 {\ textendash} 6小时,和11 \ % \ > 6小时(只有3 \ % \ > 24小时后损伤)。到达时间有显著差异的类别的损伤机制,与84 \ %机动车事故呈现在一个小时内(χ2 = 27.6,p < 0.001)。此外,年轻的病人(H = 13.6, p = 0.001),和黑色的个人(χ2 = 17.2,p = 0.002),也最有可能在一小时内到达。没有到达时间的差异类别按性别、头部CT表现或者gc。 For blood-biomarkers, there were no differences between arrival time categories for NfL, UCH-L1, and GFAP.Conclusions: Mechanism of injury, age, and race are identifiable factors that may influence both arrival time at ED and clinical outcomes and interpretation of biomarker results after TBI. Since our cohort mostly presented within 12 hours, and CT and biomarker results were not influenced, future research should focus on a small cohort of patients with ED presentation beyond 12 hours.Disclosure: Mr. Anandarajah has nothing to disclose. Alexa Walter has nothing to disclose. Dr. Gugger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceribell. The institution of Dr. Gugger has received research support from American Epilepsy Society. Cillian Lynch has nothing to disclose. Dr. Schneider has nothing to disclose. The institution of Dr. Sandsmark has received research support from NINDS. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ischemix, Inc. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pinteon Therapeutics. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from NovaSignal . Dr. Diaz-Arrastia has received stock or an ownership interest from Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/100/17_Supplement_2/3650}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }